DKDCA vs. BIAF, AIKI, ISPC, FOXO, FNVT, MNTN, AFAC, THAC, AVAC, and IQV
Should you be buying Data Knights Acquisition stock or one of its competitors? The main competitors of Data Knights Acquisition include bioAffinity Technologies (BIAF), AIkido Pharma (AIKI), iSpecimen (ISPC), FOXO Technologies (FOXO), Finnovate Acquisition (FNVT), Everest Consolidator Acquisition (MNTN), Arena Fortify Acquisition (AFAC), Thrive Acquisition (THAC), Avalon Acquisition (AVAC), and IQVIA (IQV).
Data Knights Acquisition (NASDAQ:DKDCA) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.
In the previous week, Data Knights Acquisition's average media sentiment score of 0.00 equaled bioAffinity Technologies'average media sentiment score.
Data Knights Acquisition and bioAffinity Technologies both received 0 outperform votes by MarketBeat users.
Data Knights Acquisition has higher earnings, but lower revenue than bioAffinity Technologies. Data Knights Acquisition is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.
35.3% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 45.7% of Data Knights Acquisition shares are owned by insiders. Comparatively, 36.4% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Data Knights Acquisition has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500.
Data Knights Acquisition has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -171.43%. Data Knights Acquisition's return on equity of 0.00% beat bioAffinity Technologies' return on equity.
Summary
Data Knights Acquisition beats bioAffinity Technologies on 7 of the 10 factors compared between the two stocks.
Get Data Knights Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for DKDCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DKDCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DKDCA vs. The Competition
Data Knights Acquisition Competitors List
Related Companies and Tools
